Arcus Biosciences
Income Statement

Last updated:

Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. Arcus Biosciences's past years’ income statements indicate that its last revenue has increased compared to the previous period by 4% to $117,000,000. Profit margin reached -262%. Total operating expenses were $457,000,000.

Profit Margin

Arcus Biosciences, Inc. (NYSE:RCUS): Profit margin
2016 0 -17.97M
2017 1.41M -53.08M -3756.69%
2018 8.35M -49.59M -593.73%
2019 15M -75.93M -506.21%
2020 77.51M -116.67M -150.52%
2021 382.88M 53M 13.84%
2022 112M -267M -238.39%
2023 117M -307M -262.39%

RCUS Income Statement (2016 – 2023)

2023 2022 2021 2020 2019 2018 2017 2016
Revenue
Revenue
117M112M382.88M77.51M15M8.35M1.41M0
Cost of revenue
340M14M7.05M159M78.48M02.61M0
Gross profit
-223M98M375.82M-81.48M-63.48M8.35M-1.19M0
Operating exp.
Research and development
340M288M256.34M159.34M78.48M49.64M47.21M14.24M
Selling and marketing
00000000
Total operating expenses
457M392M328.63M201.75M103.70M63.21M54.85M18.18M
Operating income
-340M-280M54.24M-124.23M-88.70M-54.85M-53.44M-18.18M
Other income (expenses), net
39M14M397K1.37M3.99M343K359K212K
Income before tax
-301M-266M54.64M-122.85M-84.71M-49.59M-53.08M-17.97M
Income tax expense
6M1M1.81M-6.18M-8.77M5.26M00
Net income
-307M-267M53M-116.67M-75.93M-49.59M-53.08M-17.97M
Earnings per share
Basic EPS
-4.15-3.710.76-2.13-1.73-1.43-1.25-0.73
Diluted EPS
-4.15-3.710.71-2.13-1.73-1.43-1.25-0.73
Data sourceData sourceData sourceData sourceData sourceData source